BioSpace News Archive

Chemomab Therapeutics Ltd. announced early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis.

Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients with schizophrenia, schizophreniform disorder or bipolar I disorder for up to four years of treatment, following treatment received in prior LYBALVI studies.

UCB, a global biopharmaceutical company, announced today that ZILBRYSQ® (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Bruker announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes.

Upstream Bio today announced the dosing of the first patients in a Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference.

Melt Pharmaceuticals, Inc., a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, provided a corporate update.

SELLAS Life Sciences Group, Inc. provided a business update and will host a corporate webinar at 8:30 am ET.

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).